The use of vision systems in robotized technology

W artykule dokonano przeglądu rozwiązań systemów wizyjnych na stanowiskach zrobotyzowanych. Zaprezentowano urządzenia wchodzące w skład takiego systemu. Dokonano klasyfikacji systemów wizyjnych ze względu na rodzaj rejestrowanego obrazu oraz ze względu na rozmieszczenie kamery lub kamer na stanowisku roboczym. Omówiono możliwości systemów wizyjnych w zależności od konfiguracji sprzętowej. Przedstawiono przebieg procesu wizyjnego rozpoczynając od akwizycji obrazu. Omówiono stosowane metody przetwarzania i analizy obrazu pochodzącego z kamer systemu wizyjnego. Pokazano także przykładowe aplikacje zrealizowane z wykorzystaniem systemów wizyjnych.The article presents an issue related to the use of vision systems at robotic stands. Devices included in such a system have been presented. The classification of vision systems was made due to the type of image being recorded and due to the location of the camera or cameras at the workstation. The capabilities of vision systems are discussed depending on the hardware configuration. The course of the video process was presented starting from image acquisition. The methods of image processing and analysis originating from video camera cameras are discussed. Also shown are examples of applications implemented using vision systems

Metabolic syndrome is associated with similar long-term prognosis in non-obese and obese patients. An analysis of 45 615 patients from the nationwide LIPIDOGRAM 2004-2015 cohort studies

Aims We aimed to evaluate the association between metabolic syndrome (MetS) and long-term all-cause mortality. Methods The LIPIDOGRAM studies were carried out in the primary care in Poland in 2004, 2006 and 2015. MetS was diagnosed based on the National Cholesterol Education Program, Adult Treatment Panel III (NCEP/ATP III) and Joint Interim Statement (JIS) criteria. The cohort was divided into four groups: non-obese patients without MetS, obese patients without MetS, non-obese patients with MetS and obese patients with MetS. Differences in all-cause mortality was analyzed using Kaplan-Meier and Cox regression analyses. Results 45,615 participants were enrolled (mean age 56.3, standard deviation: 11.8 years; 61.7% female). MetS was diagnosed in 14,202 (31%) by NCEP/ATP III criteria, and 17,216 (37.7%) by JIS criteria. Follow-up was available for 44,620 (97.8%, median duration 15.3 years) patients. MetS was associated with increased mortality risk among the obese (hazard ratio, HR: 1.88 [95% CI, 1.79-1.99] and HR: 1.93 [95% CI 1.82-2.04], according to NCEP/ATP III and JIS criteria, respectively) and non-obese individuals (HR: 2.11 [95% CI 1.85-2.40] and 1.7 [95% CI, 1.56-1.85] according to NCEP/ATP III and JIS criteria respectively). Obese patients without MetS had a higher mortality risk than non-obese patients without MetS (HR: 1.16 [95% CI 1.10-1.23] and HR: 1.22 [95%CI 1.15-1.30], respectively in subgroups with NCEP/ATP III and JIS criteria applied). Conclusions MetS is associated with increased all-cause mortality risk in non-obese and obese patients. In patients without MetS obesity remains significantly associated with mortality. The concept of metabolically healthy obesity should be revised